Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles.
Yutani S, Komatsu N, Shichijo S, Yoshida K, Takedatsu H, Itou M, Kuromatu R, Ide T, Tanaka M, Sata M, Yamada A, Itoh K. Yutani S, et al. Among authors: shichijo s. Cancer Sci. 2009 Oct;100(10):1935-42. doi: 10.1111/j.1349-7006.2009.01256.x. Epub 2009 Jun 23. Cancer Sci. 2009. PMID: 19604246 Free article. Clinical Trial.
A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer.
Noguchi M, Kakuma T, Uemura H, Nasu Y, Kumon H, Hirao Y, Moriya F, Suekane S, Matsuoka K, Komatsu N, Shichijo S, Yamada A, Itoh K. Noguchi M, et al. Among authors: shichijo s. Cancer Immunol Immunother. 2010 Jul;59(7):1001-9. doi: 10.1007/s00262-010-0822-4. Epub 2010 Feb 10. Cancer Immunol Immunother. 2010. PMID: 20146063 Free PMC article. Clinical Trial.
Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination.
Noguchi M, Mine T, Komatsu N, Suekane S, Moriya F, Matsuoka K, Yutani S, Shichijo S, Yamada A, Toh U, Kawano K, Azuma K, Uemura H, Okuno K, Matsumoto K, Yanagimoto H, Yamanaka R, Oka M, Todo S, Sasada T, Itoh K. Noguchi M, et al. Among authors: shichijo s. Cancer Biol Ther. 2010 Dec 15;10(12):1266-79. doi: 10.4161/cbt.10.12.13448. Epub 2010 Dec 15. Cancer Biol Ther. 2010. PMID: 20935522
Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele.
Sakamoto S, Matsueda S, Takamori S, Toh U, Noguchi M, Yutani S, Yamada A, Shichijo S, Yamada T, Suekane S, Kawano K, Sasada T, Hattori N, Kohno N, Itoh K. Sakamoto S, et al. Among authors: shichijo s. Cancer Sci. 2015 Oct;106(10):1257-63. doi: 10.1111/cas.12757. Epub 2015 Sep 25. Cancer Sci. 2015. PMID: 26212219 Free PMC article. Clinical Trial.
Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients.
Yutani S, Ueshima K, Abe K, Ishiguro A, Eguchi J, Matsueda S, Komatsu N, Shichijo S, Yamada A, Itoh K, Sasada T, Kudo M, Noguchi M. Yutani S, et al. Among authors: shichijo s. J Immunol Res. 2015;2015:473909. doi: 10.1155/2015/473909. Epub 2015 Oct 11. J Immunol Res. 2015. PMID: 26539554 Free PMC article. Clinical Trial.
292 results